Proteins that control mucous production and suggest clues to treating colon and airway diseases have been discovered by scientists. The findings of the study are published in the journals eLife and Journal of Biological Chemistry.
Cells produce mucins at a constant rate, and when exposed to an allergen or pathogen, they produce more mucin in a rapid burst. Both the constant and rapid mucin secretion is controlled by calcium. CRGresearchers Gerard Cantero-Recasens and Vivek Malhotra wanted to understand how normal cells secrete mucins in the right quantity and quality, so they can design procedures to correct mucin secretion defects in diseases where either too much or too little mucin is produced, such as asthma, chronic obstructive pulmonary disease, Crohn's disease and colorectal cancer.
Cystic Fibrosis
Cystic fibrosis is a genetic disease involving the mucus and sweat glands and the medical world has still to find its cure
Advertisement
‘Two proteins TRPM4 and NCX that work together to control mucin secretion both in healthy cells, and in cells derived from patients with cystic fibrosis. ’
Tweet it Now
They have also identified a third protein called KChIP3 that senses calcium levels within healthy cells to release mucins, which is crucial to maintain the correct thickness of the mucous layer in the colon. This means cells possess means to control how much mucin they produce depending on the cellular needs. They can produce large amounts if an allergen or pathogen is present, or release it constantly to preserve the mucous layer.
"First, we carried out a genome wide screen which identified 25 proteins involved in mucin secretion in colon cancer cells," explains postdoctoral researcher Cantero-Recasens. "We discovered that a group of these proteins reside on the surface of the cells to control calcium entry, which in turn controls rapid release of mucins. The team has also discovered a calcium sensor, KChIP3, inside cells that controls baseline mucin secretion, which is crucial to maintain the correct thickness of the mucous layer. If this intracellular calcium sensor is lost, it causes massive release of mucin from colonic cancer cells."
![Quiz on Cystic Fibrosis]( "Quiz on Cystic Fibrosis")
How much do you know about the chronic, progressive, inherited, fatal disease called cystic fibrosis? Learn more about cystic fibrosis from this quiz.
He continues: "We were surprised by this finding - we didn't expect that cells use different sources of calcium - from internal and external sources - to control mucin secretion. We also didn't expect to find that the KChIP3 sensor controlling baseline (basal) mucin secretion does it by acting like a 'brake' to prevent mucin release. Mice without the KChIP3 gene have a much thicker mucous layer in the colon. This means KChIP3 could be a new target for drugs to control diseases with higher or lower levels of mucins."
And by studying different cell types, the team discovered the process cells use to control stimulated mucin secretion is the same in both the colon and the airways. "This is an exciting finding because it means targeting the molecules involved in mucin secretion process can be used to treat airway diseases such as asthma or chronic obstructive pulmonary disease (COPD), as well as the colon associated pathologies," explains Dr Cantero-Recasens.
ICREA research professor at the CRG, Vivek Malhotra and his group are now working with researchers at the Hospital Del Mar and IMIM to further test whether mucins and proteins involved in mucin secretion are genetically altered in patients with diseases of the airway and colon. They are also working to find chemical means to target functions controlled by proteins in mucin secretion pathway. Together, the genetic and chemical procedures to control mucin secretion could reveal new ways to detect and control progression of asthma, chronic obstructive pulmonary disease (COPD), irritable bowel disease and colorectal cancers.
Source: Eurekalert
Quiz on Cystic Fibrosis
How much do you know about the chronic, progressive, inherited, fatal disease called cystic fibrosis? Learn more about cystic fibrosis from this quiz.
Advertisement
He continues: "We were surprised by this finding - we didn't expect that cells use different sources of calcium - from internal and external sources - to control mucin secretion. We also didn't expect to find that the KChIP3 sensor controlling baseline (basal) mucin secretion does it by acting like a 'brake' to prevent mucin release. Mice without the KChIP3 gene have a much thicker mucous layer in the colon. This means KChIP3 could be a new target for drugs to control diseases with higher or lower levels of mucins."
And by studying different cell types, the team discovered the process cells use to control stimulated mucin secretion is the same in both the colon and the airways. "This is an exciting finding because it means targeting the molecules involved in mucin secretion process can be used to treat airway diseases such as asthma or chronic obstructive pulmonary disease (COPD), as well as the colon associated pathologies," explains Dr Cantero-Recasens.
ICREA research professor at the CRG, Vivek Malhotra and his group are now working with researchers at the Hospital Del Mar and IMIM to further test whether mucins and proteins involved in mucin secretion are genetically altered in patients with diseases of the airway and colon. They are also working to find chemical means to target functions controlled by proteins in mucin secretion pathway. Together, the genetic and chemical procedures to control mucin secretion could reveal new ways to detect and control progression of asthma, chronic obstructive pulmonary disease (COPD), irritable bowel disease and colorectal cancers.
Source: Eurekalert
New COPD Management Guidelines from National Institute for Health and Care Excellence (NICE)
The National Institute for Health and Care Excellence (NICE) UK has expanded current criteria for referral of chronic obstructive pulmonary disease (COPD) patients for lung volume reduction due to recent availability of new endobronchial valve treatment.
Advertisement
 New Tool Predicts COPD Patient's at Risk of Serious ComplicationsNew Ottawa Risk Scale predicts chronic obstructive pulmonary disease (COPD) patients at risk of serious complications and will enable emergency room doctors to make better decisions about patient care. | Advertisement
|
Advertisement
Recommended Reading
Latest Respiratory Disease News
The global climate crisis is stimulating heat waves to become more frequent causing distress to people with asthma, say experts.
A new study reveals vitamin D3 supplements have encouraging effects for asthma patients. Vitamin D has a positive effect on immune response.
Hospitalization and mortality rates are on the higher side in First Nations communities than comparable populations.
To end TB by 2030, we need to decrease tuberculosis risk factors and reduce NCDs, among other vital steps to strengthen health systems.
Influenza, commonly called the flu, is an acute, contagious, respiratory tract infection, which is caused by one of the influenza viruses